slides · global inventory
Chart
Component collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 78,138
Current window 62,761-62,790
Pages 2,605
Rows per page 30
Component
62,761-62,790 of 78,138
11
The slide uses a 'before-after' logic to justify the combination strategy.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Agitate (Make it worse)Loop · Golden Circle1 hit
12
Uses a Venn diagram to show target overlap and a bar chart to show clinical efficacy improvement.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Agitate (Make it worse)Loop · Golden Circle1 hit
13
The slide uses a Gantt-style visualization to show the progress of various drug candidates (SPY001-SPY230).Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Solution (Provide relief)Loop · Quick Win Big Bet1 hit
14
The slide uses a Gantt-style visualization to show the status of various drug development programs.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Solution (Provide relief)Loop · Quick Win Big Bet1 hit
16
The chart uses a dual-axis approach to imply a safety-efficacy trade-off, positioning vedolizumab as the 'safest' and highly effective.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Solution (Provide relief)Loop · Quick Win Big Bet1 hit
20
The slide demonstrates bio-equivalence in binding affinity to a specific T-cell population.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Solution (Provide relief)Loop · Quick Win Big Bet1 hit
21
The chart compares SPY001 against two vedolizumab datasets (internal and Takeda).Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Solution (Provide relief)Loop · Quick Win Big Bet1 hit
22
Uses YTE modification as a mechanism for half-life extension.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Solution (Provide relief)Loop · Quick Win Big Bet1 hit
24
The chart compares benchmark induction remission rates with vedolizumab exposure quartiles.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Solution (Provide relief)Loop · Quick Win Big Bet1 hit
25
Data from GEMINI 1 study; highlights that higher drug concentration does not necessarily correlate with higher efficacy in maintenance.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Solution (Provide relief)Loop · Quick Win Big Bet1 hit
26
The slide uses a standard 2x2 grid for program summary and a simple timeline for catalysts.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Solution (Provide relief)Loop · Quick Win Big Bet1 hit
27
Uses historical peer data (Morphic, Prometheus) to project value inflection points for SPY001.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Solution (Provide relief)Loop · Quick Win Big Bet1 hit
29
The slide uses qualitative expert feedback to support quantitative preference share data.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Solution (Provide relief)Loop · Quick Win Big Bet1 hit
31
The chart uses a horizontal bar format to compare clinical remission percentages across different drug targets (TL1A, a4b7, IL-23s, TNFa, S1P1s, JAKs).Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Evidence1 hit
34
Includes visual representation of antibody binding mechanisms.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Evidence1 hit
37
The visual uses a mountain-climbing metaphor to represent indication expansion.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Evidence1 hit
38
The slide uses a matrix-like layout to map targets and programs against development stages.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Evidence1 hit
40
The chart uses a waterfall-style logic to show the additive effect of the combination therapy.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Evidence1 hit
43
The slide uses a Y-shaped antibody illustration to represent the combination therapy approach.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Evidence1 hit
49
The chart uses a custom range bar (min/max) with markers for IPO and Today's market cap.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Action1 hit
54
The slide uses a pentagon diagram to represent the five pillars of their antibody engineering platform.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Action1 hit
09
The chart illustrates revenue diversification across four products: VIVITROL, ARISTADA, VUMERITY, and LYBALVI.Alkermes | Results Presentation Deck | 17 slides · Alkermes
Conference presentation Investor relations Beat · Key Performance Indicator OverviewLoop · Cost Of Inaction1 hit
10
The chart displays both weekly data and a 4-week rolling average.Alkermes | Results Presentation Deck | 17 slides · Alkermes
Conference presentation Investor relations Beat · Key Performance Indicator OverviewLoop · Cost Of Inaction1 hit
11
Alkermes | Results Presentation Deck | 17 slidesAlkermes | Results Presentation Deck | 17 slides · Alkermes
Conference presentation Investor relations Beat · Key Performance Indicator OverviewLoop · Cost Of Inaction1 hit
12
The chart includes a vertical dashed line separating historical data from the most recent quarter.Alkermes | Results Presentation Deck | 17 slides · Alkermes
Conference presentation Investor relations Beat · Key Performance Indicator Overview1 hit
13
Alkermes | Results Presentation Deck | 17 slidesAlkermes | Results Presentation Deck | 17 slides · Alkermes
Conference presentation Investor relations Beat · Key Performance Indicator Overview1 hit
05
Kaplan-Meier survival curve showing probability of no relapse over 48 weeks.argenx SE | Results Presentation Deck | 15 slides · argenx
Conference presentation Investor relations Beat · ProblemLoop · Before After1 hit
08
Includes a callout for cash position at end of Q2 2023.argenx SE | Results Presentation Deck | 15 slides · argenx
Conference presentation Investor relations Beat · KPIsLoop · Pareto Focus1 hit
09
The slide highlights efficacy across different patient subsets and mentions specific clinical metrics (INCAT, I-RODS, grip strength).argenx SE | Results Presentation Deck | 16 slides · argenx
Conference presentation Investor relations Beat · Solution (Provide relief)1 hit
10
The slide uses a Kaplan-Meier plot to demonstrate clinical efficacy.argenx SE | Results Presentation Deck | 16 slides · argenx
Conference presentation Investor relations Beat · Solution (Provide relief)1 hit